AI assistant
HAEMONETICS CORP — Director's Dealing 2019
May 16, 2019
31565_dirs_2019-05-16_d60617c1-1fc2-4337-b5d4-df242fa1f679.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2019-05-14
Reporting Person: Llorens Josep (SVP, Global Manufacturing)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-14 | Common Stock | A | 1530 | — | Acquired | 2871 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-05-14 | Non-qualified Stock Option (Right to Buy) | $98.025 | A | 5342 | Acquired | 2026-05-14 | Common Stock (5342) | Direct |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested restricted stock units previously reported.
F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.